High Risk Smoldering Multiple Myeloma (HR-SMM) research hub

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

This study looks at two different drugs, linvoseltamab and daratumumab, for people with a condition called High-Risk Smoldering Multiple Myeloma (HR-SMM). Doctors want to find out if linvoseltamab is better at stopping this condition from turning into active Multiple Myeloma, a type of blood cancer.